🔎 Trials Near Me

Home › Astrocytoma › Ohio

Astrocytoma clinical trials in Ohio

8 studies for Astrocytoma are looking for participants at sites in Ohio.

Cities in Ohio

Targeted Pediatric High-Grade Glioma Therapy

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Nationwide Children's Hospital, Columbus
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
  • University of Cincinnati Cancer Center-West Chester, West Chester
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT07215910

Study of Olutasidenib and Temozolomide in HGG

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Nationwide Children's Hospital, Columbus
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Nationwide Children's Hospital, Columbus
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Nationwide Children's Hospital, Columbus
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

  • The Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05879367

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.